A detailed history of Paces Ferry Wealth Advisors, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Paces Ferry Wealth Advisors, LLC holds 1,326 shares of VRTX stock, worth $628,232. This represents 0.36% of its overall portfolio holdings.

Number of Shares
1,326
Previous 1,392 4.74%
Holding current value
$628,232
Previous $566,000 2.12%
% of portfolio
0.36%
Previous 0.39%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 01, 2024

SELL
$407.69 - $446.08 $26,907 - $29,441
-66 Reduced 4.74%
1,326 $554,000
Q4 2023

Feb 05, 2024

SELL
$343.0 - $410.68 $1,372 - $1,642
-4 Reduced 0.29%
1,392 $566,000
Q3 2023

Nov 13, 2023

SELL
$338.18 - $362.46 $10,145 - $10,873
-30 Reduced 2.1%
1,396 $485,000
Q2 2023

Jul 28, 2023

BUY
$314.42 - $351.91 $2,829 - $3,167
9 Added 0.64%
1,426 $501,000
Q1 2023

Apr 24, 2023

SELL
$283.23 - $323.1 $32,854 - $37,479
-116 Reduced 7.57%
1,417 $446,000
Q4 2022

Jan 23, 2023

SELL
$285.76 - $321.48 $14,573 - $16,395
-51 Reduced 3.22%
1,533 $0
Q3 2022

Oct 13, 2022

SELL
$273.83 - $305.53 $12,048 - $13,443
-44 Reduced 2.7%
1,584 $459,000
Q2 2022

Jul 28, 2022

SELL
$234.96 - $292.55 $103,147 - $128,429
-439 Reduced 21.24%
1,628 $459,000
Q1 2022

Apr 20, 2022

BUY
$221.42 - $260.97 $664 - $782
3 Added 0.15%
2,067 $539,000
Q4 2021

Jan 19, 2022

SELL
$177.01 - $223.45 $16,992 - $21,451
-96 Reduced 4.44%
2,064 $453,000
Q3 2021

Oct 29, 2021

BUY
$181.39 - $202.99 $391,802 - $438,458
2,160 New
2,160 $392,000
Q4 2020

Mar 05, 2021

SELL
$207.01 - $276.09 $5,589 - $7,454
-27 Closed
0 $0
Q3 2020

Nov 19, 2020

BUY
$255.65 - $303.1 $6,902 - $8,183
27 New
27 $7,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $122B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Paces Ferry Wealth Advisors, LLC Portfolio

Follow Paces Ferry Wealth Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Paces Ferry Wealth Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Paces Ferry Wealth Advisors, LLC with notifications on news.